Filing Flows › Travere Therapeutics (TVTX) › Q2 2025
Travere Therapeutics (TVTX) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 6, 2025
Travere Therapeutics (TVTX) reported revenue of $114M for the second quarter 2025 (Q2 2025), +111% from a year earlier and +40% from the quarter before. Operating margin was -11.1%, net loss $12.8M (11.1% of revenue).
Travere Therapeutics, Q2 2025: revenue $114M (+112% year over year), operating margin -11.1%, net loss $12.8M, operating cash flow $5.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $114M | +40% | +111% |
| Operating profit | −$12.7M | — | — |
| Net earnings | −$12.8M | — | — |
| Operating cash flow | $5.0M | — | — |
What changed
Revenue was $114.4M in Q2 2025, up 111% year over year and up 40% from the previous quarter. FILSPARI was the largest line at 63% of revenue. FILSPARI added $44.8M year over year (up 165%), 74% of the total change. Tiopronin products declined 8%.
Operating costs exceeded revenue by $12.7M, an operating margin of -11.1%. Total costs grew 4% against revenue growth of 111%. The fastest-growing cost line was SG&A (+18%). The quarter ended with a net loss of $12.8M, narrower than the previous quarter's $41.2M loss.
Operating cash flow was $5.0M. Non-cash charges added back $14.0M of depreciation and amortization and $10.6M of share-based compensation. Working capital and other items used $6.9M.
Questions
What was Travere Therapeutics' revenue in the second quarter 2025?
Travere Therapeutics (TVTX) reported revenue of $114M for the second quarter 2025 (Q2 2025), +111% from a year earlier and +40% from the quarter before.
Was Travere Therapeutics profitable in the second quarter 2025?
Operating loss was $12.7M (-11.1% of revenue) and net loss $12.8M.